Trial Profile
A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation HSCT
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Anti CD19 chimeric antigen receptor T cell therapy AbelZeta Pharma (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 30 Sep 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 21 Sep 2018 Planned End Date changed from 15 Dec 2019 to 30 Apr 2021.
- 21 Sep 2018 Planned primary completion date changed from 15 Oct 2019 to 28 Feb 2021.